Cleveland Clinic today announced the Top 10 Medical Innovations of 2017 at a multi-media presentation that climaxed the 2016 Medical Innovation Summit.

Topping the 11th annual list is the harnessing of the microbiome, the gut bacteria swarming in all of us. Recent discoveries have revealed the power of microbes to prevent, diagnose and treat disease. The healthcare industry will soon be pouring resources into addressing the potential for new therapies, diagnostics, probiotics and other products.

Read more

4D Pharmacueticals Produce Orally Delivered Live Biotherapeutics

Phase I Clinical Trial Generates Data on Mechanism of Action, Safety and Tolerability

4D pharma plc, a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following update on the phase 1 clinical trial in respect of Blautix, its proprietary single strain live biotherapeutic for the treatment of Irritable Bowel Syndrome (IBS).

Read more

Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial

“Metanome, Inc. has been a valuable corporate collaborator in our studies of the human microbiome delivering high-quality, genomic data in a timely manner. I’ve appreciated their responsiveness and willingness to work with Seres Health on meeting our various genomic characterization needs and look forward to continuing to work with Metanome to support our future sequencing efforts.” – Dr. Matthew Henn, Head of Therapeutic Design at Seres Health

Read more

What is Your Gut Telling You?

Scientists have long studied the link between our genes and our health. Now, in a growing area of scientific research, they’re studying the link between the bacteria in our intestines and virtually every disease that ails us.

Read more

Using the Gut Microbiome to Improve Health

Scientists analyzing the gut microbiome have found groups of bacteria that are either abundant or nearly absent – a finding that could aid in coming up with ways to intervene to improve a person’s health. Though there is gradual variation in the abundance of much of gut bacteria, the scientists said in this week’s issue of the journal Nature Communications, specific bacterial groups exist in stable configurations that are associated with a person’s physiology and health.

Read more

Architectural Design Drives the Biogeography of Indoor Bacterial Communities

Architectural design has the potential to influence the microbiology of the built environment, with implications for human health and well-being, but the impact of design on the microbial biogeography of buildings remains poorly understood. In this study we combined microbiological data with information on the function, form, and organization of spaces from a classroom and office building to understand how design choices influence the biogeography of the built environment microbiome.

Read more

The Human Gut Microbiome as a Screening Tool for Colorectal Cancer

Recent studies have suggested that the gut microbiome may be an important factor in the development of colorectal cancer. Abnormalities in the gut microbiome have been reported in patients with colorectal cancer; however, this microbial community has not been explored as a potential screen for early-stage disease. We characterized the gut microbiome in patients from three clinical groups representing the stages of colorectal cancer development: healthy, adenoma, and carcinoma. Analysis of the gut microbiome from stool samples revealed both an enrichment and depletion of several bacterial populations associated with adenomas and carcinomas.

Read more

Conducting a Microbiome Study

Human microbiome research is an actively developing area of inquiry, with ramifications for our lifestyles, our interactions with microbes, and how we treat disease.  Advances depend on carefully executed, controlled, and reproducible studies.  Here, we provide a Primer for researchers from diverse disciplines interested in conducting microbiome research. We discuss factors to be considered in the design, execution, and data analysis of microbiome studies.  These recommendations should help researchers to enter and contribute to this rapidly developing field.

Read more

CDC: Action needed now to halt spread of deadly bacteria

A family of bacteria has become increasingly resistant to last-resort antibiotics during the past decade, and more hospitalized patients are getting lethal infections that, in some cases, are impossible to cure. The findings, published today in the Centers for Disease Control and Prevention’s Vital Signs report, are a call to action for the entire health care community to work urgently – individually, regionally and nationally – to protect patients. During just the first half of 2012, almost 200 hospitals and long-term acute care facilities treated at least one patient infected with these bacteria.

Read more